Antibody-drug conjugates are big business and major deals have been struck in this area over the past year or so, with companies including Pfizer Inc., Johnson & Johnson and Merck & Co., Inc. all buying in examples of this technology.
What's Next For Phase II ADCs
BMS may have ditched an antibody-drug conjugate partnership with Eisai, but the Phase II pipeline for ADCs remains strong across the industry.
